In contrast, anlotinib combined with aPD-L1 not only enhanced CD8+ T cell infiltration but also improved the functional state of these exhausted cells, suggesting that this combination therapy enhances both the quantity and cytotoxic activity of CD8+ T cells, making them more effective at eliminating tumor cells. Here, CD8A is linked to neoplasm.